Who owns ACADIA PHARMACEUTICALS INC (ACAD)? Elite investor 13F holders

4 tracked elite investors reported holding ACADIA PHARMACEUTICALS INC as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawACADIA PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:0043033911.00 USD2135678.000000SharesaddOriginal filing
Renaissance Technologies LLCACADIA PHARMACEUTICALS INCSHARE2026-09-302026-11-12 00:00:0022316044.00 USD1107496.000000SharesreduceOriginal filing
Bridgewater AssociatesACADIA PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:00984549.00 USD48861.000000SharesreduceOriginal filing
Gotham Asset ManagementACADIA PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:00297978.00 USD14788.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown